1 a novel randomized prospective study to determine the clinical utility of HLA-B*5701 screening to reduce abacavir hypersensitivity in HIV-1 infected subjects (study CNA106030) 2008 Vol: 358:568-579. DOI: 10.1056/NEJMoa0706135


Hypersensitivity reaction to abacavir is strongly associated with the presence of the HLA-B*5701 allele. This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir.

Figure 1
  1. Phillips EJ The pharmacogenetics of antiretroviral therapy Curr Opin HIV AIDS 1, 249-256 (2006) .
  2. Hetherington S; McGuirk S; Powell G Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir Clin Ther 23, 1603-1614 (2001) .
  3. Hernandez JE, Cutrell A, Edwards M, et al. Clinical risk factors for hypersensitivity reactions to abacavir: retrospective analysis of over 8,000 subjects receiving abacavir in 34 clinical trials. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, September 14–17, 2003. Washington, DC: American Society for Microbiology, 2003:339. , .
  4. DeJesus E; Herrera G; Teofilo E Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults Clin Infect Dis 39, 1038-1046 (2004) .
  5. Gulick RM; Ribaudo HJ; Shikuma CM Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial JAMA 296, 769-781 (2006) .
  6. Staszewski S; Keiser P; Montaner J Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial JAMA 285, 285:2858.] (2001) .
  7. Mallal S; Nolan D; Witt C Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir Lancet 359, 727-732 (2002) .
  8. Hetherington S; Hughes AR; Mosteller M Genetic variations in HLA-B region and hypersensitivity reactions to abacavir Lancet 359, 1121-1122 (2002) .
  9. Martin AM; Nolan D; Gaudieri S Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant Proc Natl Acad Sci U S A 101, 4180-4185 (2004) .
  10. Hughes AR; Mosteller M; Bansal AT Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations Pharmacogenomics 5, 203-211 (2004) .
  11. Phillips EJ; Wong GA; Kaul R Clinical and immunogenetic correlates of abacavir hypersensitivity AIDS 19, 979-981 (2005) .
  12. Tesch N, Vogel M, Wasmuth JC, et al. Abacavir-associated drug hypersensitivity is strongly associated with the human leukocyte antigen B-57 allele. In: Programs and abstracts of the 8th International Congress on Drug Therapy in HIV Infection, Glasgow, Scotland, November 12–16, 2006:44. , .
  13. Rauch A; Nolan D; Martin A; McKinnon E; Almeida C; Mallal S Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study Clin Infect Dis 43, 99-102 (2006) .
  14. Reeves I; Churchill D; Fisher M Screening for HLA-B*5701 reduces the frequency of abacavir hypersensitivity Antivir Ther 11, L11-L11 (2006) .
  15. Zucman D; Truchis P; Majerholc C; Stegman S; Caillat-Zucman S Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population J Acquir Immune Defic Syndr 45, 1-3 (2007) .
  16. Phillips EJ; Sullivan JR; Knowles SR; Shear NH Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir AIDS 16, 2223-2225 (2002) .
  17. Saag M, Balu R, Phillips E, et al. High sensitivity of HLA-B*5701 in immunologically-confirmed cases of abacavir hypersensitivity in White and Black patients. Clin Infect Dis (in press). , .
  18. Phillips E, Rauch A, Nolan D, et al. Genetic characterization of patients with MHC class I mediated abacavir hypersensitivity reaction. In: Programs and abstracts of the 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, July 22–25, 2007:49. , .
  19. Phillips E; Rauch A; Nolan D Pharmacogenetics and clinical characteristics of patch test confirmed patients with abacavir hypersensitivity Rev Antivir Ther 3, 57-57 (2006) .
  20. Hughes S, Hughes A, Brothers C, et al. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. Pharm Stat (in press). , .
  21. Hernandez J; Cutrell A; Bonny T Diagnosis of abacavir hypersensitivity reactions among patients not receiving abacavir in two blinded studies Antivir Ther 8, L88-L88 (2003) .
  22. Sustiva EMEA. Summary of product characteristics. 2007. (Accessed January 11, 2008, at Link) , .
  23. Viramune EMEA. Summary of product characteristics. 2007. (Accessed January 11, 2008, at Link) , .
  24. Mosteller M, Hughes A, Warren L, et al. Pharmacogenetic (PG) investigation of hypersensitivity to abacavir. In: Programs and abstracts (vol. 2) of the XVI International AIDS Conference, Toronto, August 13–18, 2006:76. poster. , .
  25. Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome Pharmacogenet Genomics 16, 353-357 (2006) .
  26. Martin AM; Nolan D; Mallal S HLA-B*5701 typing by sequence-specific amplification: validation and comparison with sequence-based typing Tissue Antigens 65, 571-574 (2005) .
  27. Hammond E; Almeida C-A; Mamotte C External quality assessment of HLA-B*5701 reporting: an international multicentre survey Antivir Ther 12, 1027-1032 (2007) .